Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.

Active, not recruiting

Phase 1 Results N/A

Trial Description

The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.

Detailed Description

In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design.

Conditions

Interventions

  • Levetiracetam (Levetiracetam)Drug
    Other Names: Keppra
    Intervention Desc: subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design
    ARM 1: Kind: Experimental
    Label: Treatment first
    Description: Levitiracetam is started immediately after baseline data is collected.
    ARM 2: Kind: Experimental
    Label: Wait control
    Description: Levitiracetam is started after a delay.

Trial Design

  • Allocation: Non-Randomized
  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Crossover Assignment

Patient Involvement

50 post-stroke subjects with aphasia will take levetiracetam(Keppra) in an ABAB(A-On medication and B-Off Medication ) design and will undergo speech, language, and memory evaluations every 6 weeks.

Outcomes

Type Measure Time Frame Safety Issue
Primary Speech and language assessment.
Secondary Memory assessment.
Primary Speech and language assessment 6 months - 1year No
Secondary Memory assessment 6 months to 1 year No

Sponsors